201 related articles for article (PubMed ID: 17454780)
1. Maintenance immunotherapy by repetitive low-dose donor lymphocytes infusions in a child with relapse state aml after allogeneic stem cell transplantation.
Hartwig M; Weigel S; Bernig T; Bader P; Dölken R; Beck J
Pediatr Hematol Oncol; 2007 Mar; 24(2):137-40. PubMed ID: 17454780
[TBL] [Abstract][Full Text] [Related]
2. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
4. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
Loren AW; Porter DL
Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
[TBL] [Abstract][Full Text] [Related]
5. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Kremens B; Dilloo D; Sykora KW; Niemeyer C; Reinhardt D; Vormoor J; Gruhn B; Lang P; Greil J; Handgretinger R; Niethammer D; Klingebiel T; Beck JF
Bone Marrow Transplant; 2004 Apr; 33(8):815-21. PubMed ID: 14990984
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
[TBL] [Abstract][Full Text] [Related]
8. Long-term molecular remission induced by donor lymphocyte infusions for recurrent acute myeloblastic leukemia after allogeneic bone marrow transplantation.
Imoto S; Murayama T; Gomyo H; Mizuno I; Sugimoto T; Nakagawa T; Koizumi T
Bone Marrow Transplant; 2000 Oct; 26(7):809-10. PubMed ID: 11042667
[TBL] [Abstract][Full Text] [Related]
9. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
10. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
12. Successful second allogeneic peripheral blood stem cell transplantation and donor lymphocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplantation.
Ishikawa J; Maeda T; Kashiwagi H; Yoshida H; Takahashi I; Kawamoto SI; Yamada M; Kato H; Nishiura T; Tomiyama Y; Matsuzawa Y
Bone Marrow Transplant; 2003 Jun; 31(11):1057-9. PubMed ID: 12774060
[TBL] [Abstract][Full Text] [Related]
13. Induction of late graft-versus-host disease in a patient post-allogeneic stem cell transplantation by progesterone in conjunction with donor lymphocyte infusion.
Gesundheit B; Shapira MY; Maly A; Samuel S; Budowski E; Or R
Leuk Res; 2008 Mar; 32(3):501-3. PubMed ID: 17727947
[TBL] [Abstract][Full Text] [Related]
14. Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia.
Mellgren K; Fasth A; Saalman R; Olausson M; Abrahamsson J
Ann Hematol; 2005 Oct; 84(11):755-7. PubMed ID: 16001242
[TBL] [Abstract][Full Text] [Related]
16. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
[TBL] [Abstract][Full Text] [Related]
18. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.
Anderlini P; Acholonu SA; Okoroji GJ; Andersson BS; Couriel DR; De Lima MJ; Donato ML; Khouri IF; Giralt SA; Ueno NT; Champlin RE
Bone Marrow Transplant; 2004 Sep; 34(6):511-4. PubMed ID: 15273710
[TBL] [Abstract][Full Text] [Related]
19. Severe intestinal graft versus host disease after donor lymphocyte infusion; response to extracorporeal photochemotherapy.
Vural F; Donmez A; Doganavşargil B; Cagýrgan S; Alper H; Tombuloglu M
Transfus Apher Sci; 2005 Oct; 33(2):129-33. PubMed ID: 16150645
[TBL] [Abstract][Full Text] [Related]
20. Stem cell transplants for patients with relapsed/refractory leukaemia.
Kolb HJ; Simoes B; Schmid C
Curr Opin Hematol; 2009 Nov; 16(6):444-52. PubMed ID: 19652599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
